These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 21914628)
1. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Aranda R; Becker JC; Nys M; le Bars M; Reed DM; Poncet C; Dougados M Ann Rheum Dis; 2011 Nov; 70(11):2003-7. PubMed ID: 21914628 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583 [TBL] [Abstract][Full Text] [Related]
4. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
6. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. Kremer JM; Peterfy C; Russell AS; Emery P; Abud-Mendoza C; Sibilia J; Becker JC; Westhovens R; Genant HK J Rheumatol; 2014 Jun; 41(6):1077-87. PubMed ID: 24786925 [TBL] [Abstract][Full Text] [Related]
7. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
8. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Benucci M; Stam WB; Gilloteau I; Sennfält K; Leclerc A; Maetzel A; Lucioni C Clin Exp Rheumatol; 2013; 31(4):575-83. PubMed ID: 23711100 [TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T; Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370 [TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH; Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. Westhovens R; Kremer JM; Moreland LW; Emery P; Russell AS; Li T; Aranda R; Becker JC; Qi K; Dougados M J Rheumatol; 2009 Apr; 36(4):736-42. PubMed ID: 19273451 [TBL] [Abstract][Full Text] [Related]
12. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Westhovens R; Kremer JM; Emery P; Russell AS; Alten R; Barré E; Dougados M Clin Exp Rheumatol; 2014; 32(4):553-62. PubMed ID: 25005467 [TBL] [Abstract][Full Text] [Related]
14. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911 [TBL] [Abstract][Full Text] [Related]
15. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926 [TBL] [Abstract][Full Text] [Related]
16. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499 [TBL] [Abstract][Full Text] [Related]
17. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Schiff M; Bessette L Clin Rheumatol; 2010 Jun; 29(6):583-91. PubMed ID: 20099018 [TBL] [Abstract][Full Text] [Related]
20. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation]. Dejaco C; Duftner C; Wipfler E; Schirmer M Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]